Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Astermark

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Thrombosis and Haemostasis|September 10, 2021
New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with HemophiliaJan Astermark, Cihan Ay, Manuela Carvalho, et al.
Haematologica|July 2, 2011
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalitiesLars Möllgård, Leonie Saft, Marianne Bach Treppendahl, et al.
British Journal of Haematology|May 26, 2010
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapyMichael Grövdal, Mohsen Karimi, Rasheed Khan, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 22, 2022
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A - A modified Delphi consensus by the ADVANCE Working GroupRobert Klamroth, Cihan Ay, Philippe De Moerloose, et al.
The Lancet. Haematology|November 9, 2024
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trialPratima Chowdary, Pantep Angchaisuksiri, Shashikant Apte, et al.
The New England Journal of Medicine|September 25, 2024
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia BAdam Cuker, Kaan Kavakli, Laurent Frenzel, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 9, 2022
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) - Unmet needs remainErik Berntorp, Petra LeBeau, Margaret V Ragni, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 5, 2020
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)Amy D Shapiro, Margaret V Ragni, Munira Borhany, et al.
The New England Journal of Medicine|February 22, 2023
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia BSteven W Pipe, Frank W G Leebeek, Michael Recht, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 6, 2024
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical AppraisalManuela Albisetti, Jesús Ardila, Jan Astermark, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Thrombosis and Haemostasis|September 10, 2021
New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with HemophiliaJan Astermark, Cihan Ay, Manuela Carvalho, et al.
Haematologica|July 2, 2011
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalitiesLars Möllgård, Leonie Saft, Marianne Bach Treppendahl, et al.
British Journal of Haematology|May 26, 2010
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapyMichael Grövdal, Mohsen Karimi, Rasheed Khan, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 22, 2022
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A - A modified Delphi consensus by the ADVANCE Working GroupRobert Klamroth, Cihan Ay, Philippe De Moerloose, et al.
The Lancet. Haematology|November 9, 2024
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trialPratima Chowdary, Pantep Angchaisuksiri, Shashikant Apte, et al.
The New England Journal of Medicine|September 25, 2024
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia BAdam Cuker, Kaan Kavakli, Laurent Frenzel, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 9, 2022
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) - Unmet needs remainErik Berntorp, Petra LeBeau, Margaret V Ragni, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 5, 2020
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)Amy D Shapiro, Margaret V Ragni, Munira Borhany, et al.
The New England Journal of Medicine|February 22, 2023
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia BSteven W Pipe, Frank W G Leebeek, Michael Recht, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 6, 2024
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical AppraisalManuela Albisetti, Jesús Ardila, Jan Astermark, et al.
Pageof 10